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Objectives: A report from the National Emphysema Treatment Trial indicated that
lung volume reduction candidates with a forced expiratory volume in 1 second and
a diffusing capacity of carbon monoxide of 20% or less of predicted value were at
high risk for mortality and were unlikely to benefit from surgical intervention. This
article examines the applicability of the National Emphysema Treatment Trial
findings to our own patients.
Methods: We reviewed 280 patients who underwent bilateral lung volume reduction
surgery at our institution between January 1993 and December 2001. All patients
met our selection criteria, including heterogeneous distribution of emphysema. Of
these 280 patients, 20 patients had both a preoperative forced expiratory volume in
1 second and a diffusing capacity of carbon monoxide of less than or equal to 20%
of the predicted normal values, thus meeting one National Emphysema Treatment
Trial criterion for high risk. Outcomes of the 20 patients were assessed through 5
years after the operation. The survival of the 20 patient cohort was compared with
that of the 260 patients not meeting the National Emphysema Treatment Trial
high-risk criterion.
Results: Ninety-day operative mortality included 1 (5%) patient. In all patients the
forced expiratory volume in 1 second increased from 0.46 L (17%) to 0.78 L (32%),
a 73% change; the diffusing capacity of carbon monoxide increased from 16% to
27%, a 70% improvement; residual volume decreased from 6.33 L (305%) to 4.26
L (205%), a 33% improvement; and room air arterial partial pressure of oxygen
increased from 55 mm Hg to 64 mm Hg. Kaplan-Meier 5-year survivals did not
differ between the high-risk and non–high-risk groups.
Conclusions: Patients with a forced expiratory volume in 1 second and a diffusing
capacity of carbon monoxide of 20% or less of predicted value might experience
improvements in lung function, exercise tolerance, and quality of life with accept-
able morbidity and mortality after lung volume reduction surgery.
The concept of lung volume reduction as a therapy to reduce dyspneain patients with emphysema is credited to Brantigan and Mueller.1Although the initial procedure failed to gather acceptance by sur-geons, it was rediscovered and resuscitated by Cooper and col-leagues2 nearly 4 decades later. There are now long-term resultsavailable on a substantial number of patients, and the conclusion has
been that tangible benefit with acceptable risk is available to well-selected patients.3
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There has been no shortage of controversy associated with
this operation since its reintroduction in 1995. Because of
high risks and costs associated with the widespread appli-
cation of the operation in 1995, Medicare funding for the
operation was stopped as of 1996. The National Heart,
Lung, and Blood Institute of the National Institutes of
Health was tasked with devising a clinical trial to evaluate
the benefit of the procedure. The result of this effort, the
National Emphysema Treatment Trial (NETT), began en-
rolling patients in 1999.4 The NETT investigators provided
a preliminary report describing their identification of a
high-risk subset of patients for whom a high risk of surgical
intervention seemed to outweigh a low functional benefit.5
The NETT high-risk subgroup consisted of patients with
a very low forced expiratory volume in 1 second (FEV1) in
combination with a very low diffusing capacity for carbon
monoxide (DLCO), a diffuse pattern of emphysema on chest
computed tomography, or both. The high mortality seen in
such patients in the NETT prompted a modification of the
protocol to exclude from randomization any patients meet-
ing these criteria. As a direct result of the publicity sur-
rounding the NETT report of the high-risk cohort, we re-
viewed our own results in patients meeting the NETT high-
risk criteria. Because we had excluded patients with diffuse
emphysema from lung volume reduction surgery (LVRS)
from the beginning, the NETT high-risk classification cri-
terion that applied to our patients was the combination of an
FEV1 of not more than 20% of predicted value and a DLCO
of not more than 20% of predicted value. The specific
objective was to assess the appropriateness of excluding
patients with both FEV1 and DLCO of not more than 20% of
predicted value from receiving LVRS.
Methods
Patient Population
A prospective database has been maintained by the authors for all
patients undergoing LVRS, including pulmonary function studies,
exercise testing, and quality-of-life assessment. A review was
conducted from records of the 280 consecutive patients who un-
derwent bilateral LVRS at Barnes-Jewish Hospital between Janu-
ary 1993 and December 2001. This study is a retrospective anal-
ysis of prospectively acquired data. All research tests and protocols
were approved by the human studies committee, and all patients
provided informed consent for the studies and the operation. We
attempted to assess patients at 6 months, 1 year, and subsequent
yearly intervals after the operation. Many patients live a long
distance from Missouri, and we could not require their return at
fixed intervals. Follow-up data were collected during routine ap-
pointments and thus might have been collected months before or
after the desired follow-up time point. Many of these patients have
been included in previous clinical reviews of the outcomes of
LVRS in our institution, but the detailed description of this small
subset defined by NETT criteria has not been reported as a distinct
cohort.2,3,6-11
Details of the selection process have been reported previous-
ly.12 Critical selection criteria are marked hyperinflation of the
chest and sufficient regional variation in the severity of the em-
physema to provide target areas of useless lung accessible to
surgical resection. The degree of regional parenchymal destruction
is analyzed by using standardized computerized tomography of the
chest, and the regional distribution of function is assessed by
means of radionuclide ventilation-perfusion lung scanning. Tho-
racic distention is evaluated by means of chest radiography, and
lung volumes are determined with plethysmography. No special
screening was applied to the patients in this report because this
cohort of 20 patients was identified retrospectively on the basis of
NETT high-risk criteria.5
The initial evaluation includes physical examination, pulmo-
nary function testing, arterial blood gas analysis (at rest with room
air), 6-minute walk testing, and questionnaires assessing quality of
life and dyspnea. Fifty percent of more than 800 on-site evalua-
tions were excluded from surgical intervention. The most common
reason for exclusion was lack of target areas for surgical resection
(76%).3 Patients judged suitable for surgical intervention were
enrolled in a preoperative pulmonary rehabilitation program, usu-
ally for 3 months (median, 97 days). Medical therapy was opti-
mized, and dietary regimens were prescribed.
Pulmonary function tests were performed with a Medgraphics
System 1085 (Medical Graphics Corp, St Paul, Minn) before and
after administration of aerosolized albuterol, and the best values
for forced vital capacity and FEV1 were chosen for the data
analysis. Lung volumes were determined by means of plethysmog-
raphy, and diffusion capacity for carbon monoxide (DLCO) was
measured by using the single-breath technique. During the
6-minute walk test, supplemental oxygen was administered
through a nasal cannula as needed to maintain the arterial oxygen
saturation at 90% or better.
Quality of life was assessed by using the Medical Outcomes
Study 36-Item Short-Form (SF-36) Health Survey. We specifically
report the SF-36 Physical Component Summary Scale (PCS) and
the SF-36 Mental Component Summary Scale (MCS), the Physical
Functioning (PF) scale, and the response to a single question about
health now compared with 1 year prior. The PCS, MCS, and PF
scores can range from 0 (worst) to 100 (best). The PCS and MCS
scores are standardized so that the general population has a mean
 SD score of 50  10. A 10-point change in the PF score and a
3-point change in the PCS score are considered clinically impor-
tant. Patients were asked to assess their own satisfaction with the
operation on the basis of how they felt at present to measure
preoperative patient satisfaction. There are 5 possible responses:
poor, fair, good, very good, and excellent. All tests were performed
during periods of clinical stability.
A complete battery of pulmonary function tests was performed
at our institution during the postoperative follow-up periods; an
abbreviated battery of tests (FEV1 and RV) from other institutions
was also used. Follow-up evaluation also included arterial blood
gases on room air, a 6-minute walking test, and completion of
dyspnea and quality-of-life questionnaires.
Surgical Technique
All procedures were performed through a median sternotomy. The
operative technique has evolved very little since our initial expe-
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rience. In 1 of 20 patients in this report, lobar destruction and
complete fissures led to a complete lobectomy rather than wedge
excision of lung tissue. Two chest tubes were placed on each side.
The pleural space was closed bilaterally before closure of the
sternotomy. The chest tubes were brought out through the upper
abdomen in a subxiphoid position.
All patients were extubated in the operating room or shortly
thereafter in the postanesthesia recovery area. One patient required
immediate reintubation and spent the night attached to a ventilator,
with successful extubation on the following morning. The surgical,
anesthetic, and postoperative care techniques have been previously
described.2,9,13
Statistical Analysis
Descriptive statistics were expressed as means  SD unless oth-
erwise specified. Categorical data were expressed as counts and
proportions. Kaplan-Meier estimates were used to depict survival.
The log-rank test was used to compare survival between groups.
Patients who had lung transplantation after LVRS were censored
for all observations at or beyond the time of transplantation. All
data analysis was performed with Systat (Systat 10.0 for Windows;
SPSS Inc, Chicago, Ill).
Results
Patient Characteristics
The 20 patients in this report included 11 women and 9 men
with a mean age of 62.7  6 years. All had previously
smoked cigarettes, but all had quit more than 6 months
before the operation in accordance with our usual criteria.
One patient was known to have 1-antitrypsin deficiency
emphysema, and one patient had lower-lobe predominance
with lower-lobe target areas. Seven of the 20 patients used
chronic oral corticosteroids before the operation (Table 1).
Hospital Course
The hospital mortality in this series was 1 (5%) patient who
died of adult respiratory distress syndrome on postoperative
day 3 (Table 2). The most common complication was a
prolonged air leak for longer than 7 days, and this was
observed in 14 (70%) of the patients. Pneumonia was diag-
nosed in 3 (15%) patients, and respiratory failure requiring
reintubation occurred in 1 (5%) patient. Two patients had
important gastrointestinal complications, including one pa-
tient each with a small bowel obstruction and a cecal per-
foration. Reoperations were required in one patient for an
air leak, one patient for bleeding from the chest, and one
patient for the cecal perforation. The median length of
hospital stay was 12 days, with a range of 5 to 76 days and
an interquartile range of 10 to 22 days.
Follow-up Information
All 20 patients had complete vital status assessment through
the entire study period. Postoperative follow-up ranged
from 3 days for the single postoperative death to 9.3 years,
with a median follow-up of 4.6 years. Three (15%) patients
underwent lung transplantation with a mean time to trans-
plantation of 3.1  0.5 years after LVRS. There have been
11 late deaths: 7 were attributed to respiratory failure, 2 to
bronchiolitis obliterans after transplantation (mentioned for
completeness but censored in the Kaplan-Meier estimates),
and 1 each to lung cancer and myocardial infarction. The
Kaplan-Meier survival estimates are shown in Figure 1.
Functional Results
Pulmonary function test results are shown in Table 3 and
demonstrate the typical degree of improvement in spirom-
etry and exercise capability that we have reported in previ-
ous articles on our larger cohorts of patients undergoing
LVRS. It is noteworthy that the DLCO values in these pa-
tients improved from 16% of predicted value to 27% of
predicted value between the preoperative and 6-month post-
operative visits. Table 4 reports several subjective measures
of health status and quality of life. Although such measures
are prone to bias, especially when the described cohort
TABLE 1. Preoperative characteristics of high-risk pa-
tients undergoing lung volume reduction surgery
Demographics n  20
Age (y) 62.7  6.1
(range, 48.7-76.9)
Sex (female) 11 (55%)
Preoperative BMI (kg/m2) 21.1 2.8
Tobacco use 20 (100.0%)
Chronic oral steroid use 7 (35%)
Lower lobe predominant emphysema 1 (5%)
BMI, Body mass index.
TABLE 2. Hospital course for high-risk patients undergoing
lung volume reduction surgery
Event
Frequency
(n  20)
Morbidity
Prolonged air leak (7 d) 14 (70%)
Pneumonia 3 (15%)
Reintubation 1 (5%)
Small bowel obstruction/ileus 2 (10%)
Deep vein thrombosis 1 (5%)
Cecal perforation 1 (5%)
Subsequent reoperation
Prolonged air leak 1 (5%)
Bleeding 1 (5%)
GI complication 1 (5%)
Hospital mortality 1 (5%)
Postoperative hospital LOS (survivors)
Median 12 d
Range 5-76 d
IQR 10-22 d
GI, Gastrointestinal; LOS, length of stay; IQR, interquartile range.
Meyers et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 3 831
G
TS
shrinks as the follow-up gets longer, the results do suggest
a magnitude and duration of benefit that is comparable with
that seen in our previously reported large experience with
patients undergoing LVRS.3
Discussion
This retrospective analysis of 20 patients with heteroge-
neous emphysema demonstrated that some high-risk (FEV1
and DLCO 20% of the predicted normal values) patients
might experience improvements in lung function, exercise
tolerance, and quality of life with acceptable morbidity and
mortality after LVRS.
There have been many published reports describing the
outcomes after lung volume reduction, with the majority
describing a postoperative mortality of 3% to 8%. The
health technology assessment report that led to the cessation
of reimbursement by the Health Care Financing Adminis-
tration reported a mortality of 6%.14 It is typically accepted
that properly selected patients will experience a periopera-
tive mortality risk of less than 10%, with many high-volume
centers reporting mortality clustered in the 4% to 6%
range.2,15-19
Randomized controlled trials (RCTs) have advantages
over individual case series by avoiding selection and report-
ing bias. An important contribution to knowledge about a
procedure takes place when an RCT is interrupted or altered
because of findings by a data and safety monitoring board.
Two such trials have reported the need to restrict enrollment
criteria during the trial because of an excessive observed
mortality. The Geddes trial changed the enrollment criteria
after 15 enrolled patients exhibited excessive risk of death.
The trial subsequently excluded 2 groups: patients with
DLCO values of less than 30% of predicted value and pa-
tients unable to achieve a specified minimum threshold in a
pre-enrollment exercise evaluation.20 The second RCT to
adjust enrollment criteria occurred when the NETT trial
acknowledged an excessive mortality in 2 subgroups of
patients randomized to surgical intervention: patients with a
very low FEV1 and homogeneous emphysema and patients
with a very low FEV1 and a low DLCO.5
The findings in both of those trials corroborated obser-
vations from the early LVRS experience, and the statisti-
cally sound nature of a prospectively randomized trial has
added additional weight of evidence to the belief that such
patients were poor candidates. Because we have excluded
patients with a homogeneous pattern of emphysematous
destruction, our series cannot address the issue of whether
homogeneous destruction is an absolute or relative contra-
indication. The NETT high-risk article identified 140
(13.6%) of 1033 patients as belonging to the high-risk
group. Close analysis of the NETT data shows that 46
(66%) of 70 patients randomized to surgical intervention
and 48 (69%) of 70 patients randomized to medical therapy
were classified as having homogeneous emphysema and
would therefore not be representative of patients in our
series. Furthermore, the deaths reported in the NETT article
for patients with LVRS with heterogeneous emphysema and
both FEV1 and DLCO values of not more than 20% of
predicted value are 3 (12.5%) deaths in 24 patients. This
death rate is not significantly different from that presented
in the current article. The relative risk of early death in
comparable patients in the NETT article versus our own
results is 1.08 (95% confidence interval, 0.91-1.30). It
seems that the apparent differences in outcome between the
NETT high-risk patients and our own patients declared high
risk by using the NETT criteria disappear when the patients
with homogenous emphysema are excluded from the anal-
ysis.
The NETT high-risk patients fell into 2 subgroups, both
of which had an FEV1 of less than or equal to 20% of
predicted value. The first group had a homogeneous pattern
of emphysematous destruction (n  94), and the second
group had a DLCO of less than or equal to 20% of predicted
value (n 87). However, when the outcomes were reported
as survival curves, the results of each subgroup were dis-
played without emphasizing the substantial overlap (n 
41) of patients who met all 3 criteria. Rather, 2 overlapping
groups of patients were displayed: all patients with FEV1
values of not more than 20% and homogeneous emphysema
and all patients with DLCO and FEV1 values both not more
than 20%. In the overlap group patients with all 3 charac-
teristics are reported twice because they appear in each of
the previous groups. The true 2-factor groups were never
described apart from the very high-risk patients in the
overlap group.
We do agree that patients with severe functional impair-
ment, as reflected by both an FEV1 and a DLCO of 20% or
less of predicted value might still represent relatively high-
risk patients. The small number of patients presented here
makes the mortality estimate of 5% susceptible to large
fluctuations in the event of 1 or 2 deaths in future patients
Figure 1. Kaplan-Meier survival graph after LVRS.
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meeting this criterion. The median hospital stay was 3 days
longer for the patients in this current report than for the
recently reported larger cohort from which they were
drawn.3 It is also important to point out that the rates of
prolonged air leak and pneumonia were higher in these
patients than in the larger cohort, although these differences
do not reach statistical significance. It is our habit to give
thorough counseling to such patients about the possibility of
lung transplantation as an alternative to lung volume reduc-
tion. Patients with severe destruction and homogeneous
emphysema are steered preferentially toward transplanta-
tion because of our bias that LVRS requires heterogeneous
target areas to be effective.
The DLCO determination does have limitations in its role
as an exclusionary criteria for LVRS. One such limitation is
the fact that many physiologic processes can lead to a low
DLCO. For instance, it might result from combinations of
extensive loss of diffusing surface caused by emphysema-
tous destruction of alveolar walls and capillaries, thickening
of the alveolar-capillary interface, reduction of red cells in
capillaries, and marked hypoventilation of potentially func-
tional pulmonary parenchyma. It has been the authors’
belief that in heterogeneous emphysema compression of the
spared lung by the diseased areas leads to focal hypoventi-
lation and underestimation of the DLCO. Recruitment of
capillaries after LVRS might account for an increase in
TABLE 3. Pulmonary function testing in high-risk patients undergoing lung volume reduction surgery
After rehab,
preoperative
6 months
postoperatively
1 y
postoperatively
3 y
postoperatively
5 y
postoperatively
N 20 19 19 14 6
FEV1, L (% predicted) 0.46 0.1 (17%) 0.78 0.3 (32%) 0.81 0.3 (31%) 0.74 0.3 (25%) 0.66 0.2 (24%)
% Change* NA 73 63 82 72 47 91 36 52
DLCO, mL · min1 · mm Hg1
(% predicted)
4.2 0.9 (16%) 7.0 3.1 (27%) 7.2 3.2 (28%) 6.9 3.4 (26%) 6.2 2.3 (25%)
% Change* NA 70 82 78 92 66 88 50 42
RV, L (% predicted) 6.33 1.2 (305%) 4.26 1.1 (205%) 4.26 0.97 (202%) 5.29 1.4 (242%) 6.38 1.77 (267%)
% Change* NA 33 17 32 13 14 26 13 16
PaCO2, mm Hg 46.6 6.0 40.3 6.4 40.3 5.9 42.2 6.7 46.4 5.0
PaO2, mm Hg 55.2 7.5 64.1 13.8 66.7 11.4 70.3 12.3 68.5 4.1
O2—Continuous/with exercise 60%/100% 32%/74% 22%/77% 50%/93% 57%/100%
Six-min walk, ft 913 235 1158 289 1179 295 1124 322 1100 205
% Change* NA 27 41 28 39 26 42 25 23
MRC dyspnea score 3.1 0.9 1.5 0.9 1.6 0.9 2.1 0.92 2.4 0.8
FEV1, Forced expiratory volume in 1 second; DLCO, diffusing capacity of carbon monoxide; RV, residual volume; MRC, medical research council.
*The mean percentage change of postoperative value from preoperative (postrehabilitation) value.
TABLE 4. Quality of life and satisfaction in high-risk patients undergoing lung volume reduction surgery
After rehab
6 mo
postoperatively
1 y
postoperatively
3 y
postoperatively
5 y
postoperatively
N 20 19 19 14 6
SF-36 Physical Functioning 9.8 11.0 44.5 23.9 41.1 26.6 29.3 28.2 32.1 21.4
SF-36 PCS 25.2 7.1 31.9 10.4 31.9 11.6 27.0 11.7 28.4 9.5
SF-36 MCS 45.7 9.9 53.6 10.0 53.6 11.1 52.2 9.2 58.8 9.7
“Compared to one year ago, how would you rate your health in general now?”
Much better NA 10 (52.6%) 10 (52.6%) 0 (0%) 0 (0%)
Somewhat better NA 6 (31.6%) 6 (31.6%) 0 (0%) 0 (0%)
About the same NA 2 (10.5%) 1 (5.3%) 5 (35.7%) 4 (66.6%)
Somewhat worse NA 1 (5.3%) 1 (5.3%) 4 (50.0%) 2 (33.3%)
Much worse NA 0 (0%) 1 (5.3%) 2 (14.3%) 0 (0%)
Patient satisfaction with surgery
Excellent NA 8 (42.1%) 7 (36.8%) 6 (42.9%) 2 (33.3%)
Very good NA 7 (36.8%) 7 (36.8%) 0 (0%) 1 (16.7%)
Good NA 3 (15.8%) 2 (10.5%) 4 (28.6%) 1 (16.7%)
Fair NA 1 (5.3%) 2 (10.5%) 3 (21.4%) 1 (16.7%)
Poor NA 0 (0%) 1 (5.3%) 1 (7.1%) 1 (16.7%)
PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary.
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DLCO after resection of 20% to 30% of the lung paren-
chyma.
Another limitation of the DLCO is the problem of repro-
ducibility. To evaluate the test-to-test variability of measur-
ing the DLCO, we performed an exploratory analysis of our
preoperative patients before and after pulmonary rehabili-
tation. In the initial evaluations of 280 patients undergoing
LVRS, 63 (23%) had FEV1 values of less than 20%, and 34
(12%) had DLCO values of less than 20%, with 13 (5%)
patients meeting both criteria. However, after rehabilitation
and immediately before the operation, 69 (25%) patients
had FEV1 values of less than 20%, and 40 (14%) had DLCO
values of less than 20%, with 20 (7%) patients meeting both
criteria. The fact that the cohort described in this article
could vary from 13 to 20 patients on the basis of measure-
ments taken a few weeks apart suggests that a fixed cut-off
point of DLCO or FEV1 applied to the selection criteria for
LVRS would be inappropriate.
A limitation of this study is the retrospective nature of
the analysis. We did not collect a full set of initial data on
all patients referred for consideration for LVRS, and as a
result, we have no ability to estimate what fraction of all
patients with the criteria in question (FEV1 and DLCO 20%
of predicted value) were actually selected for surgical in-
tervention. Presumably, as one or more relative contraindi-
cations are encountered, there must be other favorable cri-
teria, such as youth or motivation, that tip the decision
toward acceptance for LVRS. We performed an exploratory
analysis to see whether the patients undergoing LVRS in
our series had some evidence of selection bias in the form of
favorable measurements on other known risk factors, such
as sex, age, and exercise capability. These data (not shown)
suggested an overrepresentation of female patients but did
not otherwise support the hypothesis that the patients in this
report had favorable observations on other covariables to
explain their selection or their favorable outcome. Further-
more, there are no data about patients selected with such
criteria who might have embarked on the preoperative re-
habilitation and either failed to complete it or declined
during that period to the extent that they were rendered
unacceptable for the risk of surgical intervention.
Conclusion
These results of LVRS in patients with both DLCO and FEV1
values of not more than 20% of the predicted normal values
are in contrast to the results of the NETT high-risk report of
2001. Although it is difficult to generalize on the basis of the
experience obtained with 20 carefully selected patients,
these results show acceptable mortality, functional outcome,
and long-term survival in this defined cohort. Individual
patients referred for LVRS should be evaluated on the basis
of all information available, and a hasty exclusion on the
basis of the 2 variables, FEV1 and DLCO, might exclude
reasonable candidates from consideration.
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Discussion
Dr Douglas E. Wood (Seattle, Wash). Bryan, you have done
your usual excellent job in the selection of an important study
question, the analysis of your results, and a concise and clear
presentation. I would like to emphasize to the audience that the
manuscript is of equal quality and is a good read that is worth your
time when it is published.
Although the much awaited primary outcomes of the NETT
will be published in 2 weeks, to date, the NETT has published only
the outcomes of this high-risk subgroup of patients that you have
referenced, a group with modest functional benefit that was offset
in the NETT by increased morbidity and mortality. You were right
to question and challenge this conclusion with your own experi-
ence.
There is a subgroup of patients with heterogenous disease and
low FEV1 and DLCO values with which comparisons can be made.
Although your morbidity and mortality are somewhat similar to
those of the NETT cohort, your patients were able to achieve a
substantial clinical benefit compared with their baseline values.
The beneficial functional outcomes potentially make the morbidity
and mortality acceptable and call into question whether these
criteria should be considered absolute contraindications, as sug-
gested by the NETT. However, the NETT accepted all patients
with these criteria, whereas you might have been able to select for
other factors that overcome these risks.
Do you have an estimation of the number of patients with these
clinical characteristics that were excluded from surgical interven-
tion in your series, and do you have any ideas of factors that might
have allowed better selection in your patients? Your group and
others have postulated specific selection criteria to achieve optimal
outcomes after LVRS. How would you propose that we challenge
the extent or the limitations of these criteria and determine whether
additional patients might benefit from lung reduction for emphy-
sema?
Bryan, I appreciate the work of you and your group in this
arena. I hope that others will examine their own experience with
these high-risk patients to help define whether selected patients
might be able to be offered LVRS in spite of NETT suggestions to
the contrary. Thank you.
Dr Meyers. Thanks for your comments. The first question was
an estimation of the fraction of patients who presented with these
risk factors who were actually selected for surgical intervention,
and unfortunately, we do not have that information. We did not
collect a full set of data on patients who were evaluated and then
not chosen for the operation. It turns out that this is 7% of the total
population of patients who underwent LVRS.
As I pointed out earlier, in the NETT it was 13% of patients that
constituted the high-risk group. But I think if you consider only the
heterogeneous patients within the NETT, the overall fraction of
patients represented in our group is comparable with the fraction of
heterogenous patients in the NETT.
With regard to challenging the limitations that are placed on the
operation, I think that the most important thing would just be
ongoing discussion of subgroups of patients of interest and con-
stantly being alert to any trends that develop in terms of poor or
excellent outcomes, and I think forums such as this are useful.
There is generally a bias toward the presentation of favorable
results, and I think that we also have to be very tuned in to the
potential of report bias in terms of extrapolating from presented or
published work and using that as selection criteria for further
operations.
Dr Thomas M. Egan (Chapel Hill, NC). That was a nice
presentation, Bryan. You mentioned that your actuarial survival
analysis censored patients at the time of lung transplantation, and
I was curious to learn whether your high-risk group had a higher
incidence of lung transplantation than your low-risk group?
Dr Meyers. Of the subgroups that we have categorized, the
patients who have had LVRS for lower-lobe emphysema or 1-
antitrypsin deficiency emphysema are the one subgroup that
emerged as having a higher rate requiring lung transplantation than
any other group. As far as the 20 high-risk patients presented here,
their rate of transplantation is not statistically different from that of
the rest of the cohort.
Dr Jean Deslauriers (Ste Foy, Quebec, Canada). Do you think
it is possible that both conclusions are quite right here? The NETT
trial involves many surgeons that do probably very few proce-
dures. In the general community you should really select patients,
and these are some of the criteria that you can use for selection. On
the other hand, in a large center like St Louis, where many cases
are done every month, then you can extend the criteria and operate
on higher-risk patients. What I understand here today is that there
are 2 different points of view, and I think they are not exclusive.
I think the conclusions are probably right as they apply to the
center that you work in.
Dr Meyers. I agree with your comment. I think that, particu-
larly if you compare the results of the NETT in heterogeneous
patients and the results that I have just described, there is no
statistical difference in terms of survival between those 2 very
careful comparisons. Therefore I definitely agree with your com-
ments.
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